Skip to content
Ejaculation.org

Meta-analysis · 2009

Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis

Serretti A, Chiesa A (2009). Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis. Journal of Clinical Psychopharmacology. doi:10.1097/JCP.0b013e3181a5233f

Key finding
Pooling studies that asked directly about sex, sertraline, venlafaxine, citalopram, paroxetine, fluoxetine and escitalopram caused more sexual dysfunction than placebo (25.8% to 80.3% of patients), while bupropion and mirtazapine did not differ from placebo.

Summary

Sexual side effects of antidepressants are underestimated because patients rarely report them unless asked. This meta-analysis therefore pooled only studies in which sexual function was investigated through direct questions and specific questionnaires, in patients without sexual problems before treatment. The main outcome was the rate of new sexual dysfunction, with secondary outcomes for desire, arousal and orgasm problems.

Compared with placebo, the following drugs caused significantly more sexual dysfunction, in decreasing order of impact: sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, imipramine, phenelzine, duloxetine, escitalopram and fluvoxamine, with sexual dysfunction in 25.8% to 80.3% of patients. Agomelatine, amineptine, bupropion, moclobemide, mirtazapine and nefazodone did not differ significantly from placebo.

Limitations

The authors note that including open-label studies and the use of different questionnaires could reduce the reliability of the findings. Studies varied in dose, duration and population. Some of the drugs listed are not available in every country.

What it means for you

Sexual side effects, including delayed ejaculation and orgasm, are common with many antidepressants and vary a lot between drugs. That variation is why a prescriber may be able to adjust or change your medicine, rather than you having to choose between your mood and your sex life.